

Tender Reference no.-BMSIC/DRUGS/18-03

S.N.		Technical Eligibility Criteria as per NIT																																																									
		Firm Name - UNICURE INDIA LIMITED Corporate Address:- C-677, NEW FRIENDS COLONY, NEW DELHI-110025 Manufacturer Address:- C-21, 22 & 23, SECTOR-3, NOIDA-201301, DIST.-GAUTAM BUDDH NAGAR. (U.P)																																																									
1	Constitution of the Bidding Company/Firm such as Memorandum of Association and Article of Association with complete address. As per Clause 3(c).	(a) Scanned copy of Bidder information/Bidder details as per Annexure-V is submitted. [Pg. no.-129] (b) Scanned copy of Memorandum of Association of M/s Unicare India Ltd. is submitted. [Pg. no.19 to 27] (c) Scanned copy of Articles of Association of M/s Unicare India Ltd. is submitted. [Pg. no.9 to 18] (d) Scanned copy of certificate of incorporation (No10642 of 1980-81 dated 14-07-1980) of M/s Unicare (India) Private Limited is submitted. [Pg. no.-28] (e) Scanned copy of Fresh certificate of Incorporation (Corporate Identity Number- U74899DL1980PLC010642 dated 12-03-2013) consequent upon change of Name from M/s Unicare India Pvt. Ltd. to M/s Unicare India Ltd. is submitted. [Pg. no. - 29]																																																									
2	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3 (e) of the NIT.	(a) Scanned and notarised copy of Power of Attorney on non judicial stamp paper of Rs-10/- is submitted wherein it is stated that I Abdul Mateen, Managing Director of M/s Unicare India Ltd. hereby assign the power of Attorney to Mr. Rupesh kumar age 32 yrs s/o- Late Purshotam Prasad Sharma resident at A-7, P.C. Colony, Kankarbagh Patna - 20 to sign all tender documents against rate contract of drugs in tender floated by BMSICL, Patna. [Pg. no.-4] (b) Scanned Copy of Extract of the Minute's of the Board of Directors of M/s Unicare India Ltd. held on 17.04.2018 is submitted wherein it is further resolved that Rupesh Kumar is hereby Authorized to file the tender for the company directly where he will obtain necessary documents to fulfill the terms of the conditions, sign bid document on behalf of the company with seal, enter any type of agreement with above, attend the meeting whenever called by BMSICL and in process represent company whenever required for signing any type of contract. (pg. no. 5)																																																									
3	List of item Quoted in prescribed format as Annexure III as per Clause 3 (o)	Scanned copy of List of items quoted is submitted as per Annexure III of NIT (Total no. of items quoted is 13) (Pg no- 63 to 64) <table> <thead> <tr> <th>NIT S.No.</th><th>Name of the Drug</th><th>Specification</th><th>Pack size</th></tr> </thead> <tbody> <tr> <td>6</td><td>Sulphadoxine + Pyrimethamine Tablets IP</td><td>500 mg +25mg</td><td>10 x 10</td></tr> <tr> <td>7</td><td>Norethisterone Tablets IP</td><td>5 mg</td><td>10 x 10</td></tr> <tr> <td>10</td><td>Artesunate Tablets</td><td>50 mg</td><td>10 x 10</td></tr> <tr> <td>34</td><td>Methyldopa Tablets IP</td><td>500 mg</td><td></td></tr> <tr> <td>42</td><td>Promethazine Syrup IP</td><td>5mg/ 5ml</td><td>60 ml</td></tr> <tr> <td>43</td><td>Clotrimazole Pessaries IP</td><td>100 mg</td><td>1's</td></tr> <tr> <td>44</td><td>Miconazole Cream IP</td><td>2% w/w</td><td>15 Gm Tube</td></tr> <tr> <td>45</td><td>Chlorpheniramine Tablets IP</td><td>4 mg</td><td>10 x 10</td></tr> <tr> <td>46</td><td>Diazepam Tablets IP</td><td>5 mg</td><td>10 x 10</td></tr> <tr> <td>47</td><td>Doxycycline Capsules IP</td><td>100 mg</td><td>10 x 10</td></tr> <tr> <td>48</td><td>Diclofenac Gel</td><td>1% w/w</td><td>30 gm</td></tr> <tr> <td>49</td><td>Paracetamol Syrup IP</td><td>125 mg/ 5ml</td><td>60 ml</td></tr> <tr> <td>54</td><td>ACT Combi Pack (Pink Colour)</td><td>3 Tablets of Artesunate (25 mg)+ 1 Tablet of Sulfadoxine + Pyrimethamine (250 mg + 12.5 mg)</td><td></td></tr> </tbody> </table>	NIT S.No.	Name of the Drug	Specification	Pack size	6	Sulphadoxine + Pyrimethamine Tablets IP	500 mg +25mg	10 x 10	7	Norethisterone Tablets IP	5 mg	10 x 10	10	Artesunate Tablets	50 mg	10 x 10	34	Methyldopa Tablets IP	500 mg		42	Promethazine Syrup IP	5mg/ 5ml	60 ml	43	Clotrimazole Pessaries IP	100 mg	1's	44	Miconazole Cream IP	2% w/w	15 Gm Tube	45	Chlorpheniramine Tablets IP	4 mg	10 x 10	46	Diazepam Tablets IP	5 mg	10 x 10	47	Doxycycline Capsules IP	100 mg	10 x 10	48	Diclofenac Gel	1% w/w	30 gm	49	Paracetamol Syrup IP	125 mg/ 5ml	60 ml	54	ACT Combi Pack (Pink Colour)	3 Tablets of Artesunate (25 mg)+ 1 Tablet of Sulfadoxine + Pyrimethamine (250 mg + 12.5 mg)		
NIT S.No.	Name of the Drug	Specification	Pack size																																																								
6	Sulphadoxine + Pyrimethamine Tablets IP	500 mg +25mg	10 x 10																																																								
7	Norethisterone Tablets IP	5 mg	10 x 10																																																								
10	Artesunate Tablets	50 mg	10 x 10																																																								
34	Methyldopa Tablets IP	500 mg																																																									
42	Promethazine Syrup IP	5mg/ 5ml	60 ml																																																								
43	Clotrimazole Pessaries IP	100 mg	1's																																																								
44	Miconazole Cream IP	2% w/w	15 Gm Tube																																																								
45	Chlorpheniramine Tablets IP	4 mg	10 x 10																																																								
46	Diazepam Tablets IP	5 mg	10 x 10																																																								
47	Doxycycline Capsules IP	100 mg	10 x 10																																																								
48	Diclofenac Gel	1% w/w	30 gm																																																								
49	Paracetamol Syrup IP	125 mg/ 5ml	60 ml																																																								
54	ACT Combi Pack (Pink Colour)	3 Tablets of Artesunate (25 mg)+ 1 Tablet of Sulfadoxine + Pyrimethamine (250 mg + 12.5 mg)																																																									

Annexure
12/6/18

Annexure
12/6/18

Annexure
12-6-18

Annexure
12/6/18

Annexure
12/6/18

Annexure
12/6/18

Annexure
(11-16)

Annexure
12/6/2018

(a) Scanned copy of Manufacturing Licence in Form-25 [Licence to Manufacture for sale of drugs other than those specified in schedules C and C(1)] issued by Drugs Controller U.P. is submitted wherein it is stated that Licence no 3 of 1984 of M/s Unicare (India) Pvt. Ltd. Ghaziabad shall be in force from 03.01.1984 to 31.12.1985. [Pg. no.-62]

Note- Submitted Manufacturing Licence in Form-25 which is not in accordance to Drugs and Cosmetics Act 1940 - "Licence to manufacture for sale or for distribution of drugs other than those specified in [Schedules C and C(1) and XI]"

(b) Scanned copy of Manufacturing Licence in Form-28 [Licence to Manufacture for sale drugs specified in schedules C and C(1)] issued by Drugs Controller U.P. is submitted wherein it is stated that Licence no 3/SC/P of 1984 of M/s Unicare (India) Pvt. Ltd. Ghaziabad shall be in force from 03.01.1984 to 31.12.1985. [Pg. no.-61]

Note-Submitted Manufacturing Licence in Form-28 which is not in accordance to Drugs and Cosmetics Act 1940 - "Licence to manufacture for sale or for distribution of drugs specified in Schedules C and C (1) [excluding those specified in Schedule X]"

(c) Scanned copy of certificate (No.-Drug/1666/5137 dated. 14-08-2013) issued by Drug licensing cum controlling Authority (U.P.) is submitted wherein it is stated that the company M/s Unicare (India) pvt. Ltd. has been changed to M/s Unicare (India) Ltd. is submitted. [Pg. no.-60]

(d) Scanned copy of certificate of Renewal in Form 26 (Certificate of renewal of licence to manufacture for sale of drugs other than those specified in Schedule X) signed on 20-03-2012 by Drug licensing & controlling Authority (U.P.) is submitted wherein it is stated that licence No.-03 of 1984 & 03/SC/P of 1984 of M/s Unicare (India) Ltd. Noida, Distt- Gautam Budh Nagar(U.P.) for the manufacture of the following categories of drugs other than those specified in Schedule C, C(1) & X, have been renewed from 01-01-2012 to 31-12-2016. [Pg. no.-123]

Note-(i) The two highlighted sentences in form 26 are contradictory.

(ii) **Stamp and Seal of Drug Control Department is not observed in Form 26.**

(e) Scanned copy of Approved Product List signed on 20.03.2012, 14.08.2013 & 13.01.2014 is submitted. (Pg. no-113 to 122).

i) For the Product at NIT sl. no 6- Pyrimethamine & Sulphadoxine Tablets IP with **Brand Name UNIKELFIN TABLETS** (Pg. no-119)

ii) For the Product at NIT sl. no 7- Norethisterone Tablets IP 5 mg (Pg. no-117)*

iii) For the Product at NIT sl. no 10- **ALDESIN TABLETS** (Artesunate Tablets 50 mg) (Pg. no-118)

iv) For the Product at NIT sl. no 34- Methyldopa Tablets IP 500 mg (Pg. no-111)

v) For the Product at NIT sl. no 42- Promethazine Syrup IP (Pg. no-113)

vi) For the Product at NIT sl. no 43- Clotrimazole Vaginal Tablets IP 100 mg (Pg. no-120)

vii) For the Product at NIT sl. no 44- Miconazole Nitrate Cream IP 2% w/w (Pg. no-115)

viii) For the Product at NIT sl. no 45- Chlorpheniramine Tablets IP 4 mg (Pg. no-122)

ix) For the Product at NIT sl. no 46- Diazepam Tablets IP 5 mg (Pg. no-121)

x) For the Product at NIT sl. no 47- Doxycycline Capsules IP 100 mg (Pg. no-116)

• Minimum three years old valid manufacturing licence of the product quoted with latest license renewal certificate. As per clause 3(f).

• Approved product list as per the license issued for quoted drugs for minimum three years. As per clause 3(f).

• Manufacturing License along with approved product list must be valid till the last date of the submission of tender. As per clause 3(f).

• In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.

• Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Organization). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be

Amr
19/6/18

Hm
12/9/18

hmt
12-06-18

Vijay
12/6/18

Amr
18/9/18

Amr
12/9/18

Amr
12/9/18

	<p>relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall apply.</p> <p>For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.</p> <p>• FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.</p> <p>Bidders shall submit self attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. As per Clause 3(f)</p>	<p>(xi) For the Product at NIT sl. no 48- Diclofenac Gel BP with Brand Name OITIS GEL (Pg. no- 114)</p> <p>xii) For the Product at NIT sl. no 49- Paracetamol Syrup IP 125 mg/ 5ml (For Paediatric use) (Pg. no- 113)</p> <p>xiii) For the Product at NIT sl. no 54- Combi Blister Pack of Artesunate Tablet, Pyrimethamine & Sulphadoxine Tablet. (Pyrimethamine, Sulphadoxine & Artesunate Kit) (Age Group 0-01 years) (Pg. no- 112)</p> <p>(f) Scanned copy of certificate of Renewal in Form 26 (Certificate of renewal of licence to manufacture for sale of drugs other than those specified in Schedule X) signed on 02-02-2017 by Drug licensing & controlling Authority (U.P.) is submitted wherein it is stated that licence No.-03 of 1984 & 03/SC/P of 1984 of M/s Unicare (India) Ltd. Noida, Distt- Gautam Budh Nagar(U.P.) for the manufacture of the following categories of drugs other than those specified in Schedule C, C(1) & X, have been renewed from 01-01-2017 to 31-12-2021.</p> <p>Note-(i) The two highlighted sentences in form 26 are contradictory.</p> <p>(ii) Stamp and Seal of Drug Control Department is not observed in Form 26.</p> <p>(g) Scanned copy of Approved Product List signed on 02.02.2017 is submitted. (Pg. no- 45 to 58)</p> <p>i) For the Product at NIT sl. no 6- Pyrimethamine & Sulphadoxine Tablets IP (Pg. no-54)</p> <p>ii) For the Product at NIT sl. no 7- Norethisterone Tablets IP 5 mg (Pg. no-52)</p> <p>iii) For the Product at NIT sl. no 10- Artesunate Tablets 50 mg (Pg. no- 53)</p> <p>iv) For the Product at NIT sl. no 34- Methyldopa Tablets IP 500 mg (Pg. no- 56)</p> <p>v) For the Product at NIT sl. no 42- Promethazine Syrup IP 5.0 mg/ 5ml (Pg. no-47)</p> <p>vi) For the Product at NIT sl. no 43- Clotrimazole Vaginal Tablets IP 100 mg (Pg. no-55)</p> <p>vii) For the Product at NIT sl. no 44- Miconazole Nitrate Cream IP 2% w/w (Pg. no-50)</p> <p>viii) For the Product at NIT sl. no 45- Chlorpheniramine Tablets IP 4 mg (Pg. no-58)</p> <p>ix) For the Product at NIT sl. no 46- Diazepam Tablets IP 5 mg (Pg. no-57)</p> <p>x) For the Product at NIT sl. no 47- Doxycycline Capsules IP 100 mg (Pg. no- 51)</p> <p>xi) For the Product at NIT sl. no 48- Diclofenac Gel BP 1.16 % w/w (Pg. no- 49)</p> <p>xii) For the Product at NIT sl. no 49- Paracetamol Syrup IP 125 mg/ 5ml (For Paediatric use) (Pg. no- 48)</p> <p>xiii) For the Product at NIT sl. no 54- Anti Malarial Combi Blister Pack (Infant) (Pg. no- 46)</p> <p>Note- Pack Size is not mentioned in Approved Product List.</p> <p>i) Scanned copy of certificate (no.-Drug/1666/3531 dated-06-06-2017) issued by Drug Licensing and Controlling Authority Uttar Pradesh (India) is submitted wherein it is stated that M/s Unicare India Ltd. is manufacturing & Marketing the following Drugs and non of the following drug permissions have been cancelled in the last 3 years. Product at NIT sl. no. 6, 7, 10, 34, 42, 43,44, 45, 46, 47, 48, 49 and 54 are mentioned in above certificate. (Pg. no- 31 to 43 & 110)</p>
5	In case of Importer, the bidder (importer) firm must have minimum three years old valid import license of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender. As per Clause 3(g)	NA
6	Self attested copies of Market standing certificate (in India) of minimum three years, issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. As per Clause 3(h)	NA
7	Self attested copy of Non Conviction Certificate (NCC), issued by the concerned Licensing Authority from Drug Control Administration of the state for last three years. It should be not more than one year old. As per Clause 3(i).	<p>Scanned Copy of Non conviction Certificate (No. Drug/1666/5502 dated 10.11.2017) issued by Drug Licensing and Controlling Authority, Uttar Pradesh is submitted wherein it is stated that M/s Unicare (India) Ltd. has not been convicted for violation of provisions of Drugs & Cosmetics Act. 1940 & Rules there under, during the preceding five years. Above Certificate is Valid for six months from the date of issue.</p> <p>(Pg. no. 7)</p> <p>Note- Non Conviction Certificate is not valid as last date of submission of online bid is 23.05.2018 as per Corrigendum- III</p>

48

448

8	Self attested copies of WHO-GMP/GMP as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority / Drugs Control Department. The GMP certificate must not be older than one year from the last date of submission of tender. As per clause 3(l).	(a) Scanned Copy of certificate of Good Manufacturing practices (No. Drug/1666/149 dated 17/01/2018) issued by Drug Licensing and controlling Authority, UP is submitted wherein it stated that on the basis of the inspection carried out on 15.11.2017 we certified that M/s Unicare India Ltd. Complies with Good Manufacturing practices for the dosage forms, categories and activities listed in Table 1. This Certificate remains valid upto 16.01.2019 (Page No. 71) (b) Scanned Copy of certificate (No. Drug/1666/150 dated 17/01/2018) issued by Drug Licensing and controlling Authority, UP is submitted wherein it is further certified that M/s Unicare India Ltd. Complying the provision of revised Schedule "L-1" (Good Laboratory practices) of Drugs and Cosmetics Rules 1945. This Certificate is valid for one year from the date of issue. (Page No. 70)
9	Self attested copies of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department highlighting the quoted product section. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importers will have also to submit Invoices/Evidence of import in items of said product with quantity details. As per Clause 3(k).	Scanned Copy of Certificate (No. Drug/1666/309 issue dt. 15/01/2013) issued by Drugs Licensing cum Controlling Authority, UP is submitted wherein the prequalified installed capacity of M/s Unicare (India) Pvt. Ltd. is mentioned as (1) Tablets - 199-20 Crores, (2) Capsules 21.84 crores, (3) Sachets 2.30 Crores, (4) Creams 120 Tons, (5) Ointments 120 Tons (6) Liquid Orals 172.80 Lac Bottles. (Pg. no. 2 to 3) Note:-1) This certificate is for M/s Unicare (India) Pvt. Ltd.
10	An affidavit (with stamp) sworn before first class magistrate/Notary stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT).	Scanned copy of notarised affidavit for Non-Blacklisting is submitted as per Annexure II of NIT (pg. no. 90 to 91)
11	EMD details (DD number/BG number and date with issuing bank) as per Clause 3(b).	CANARA BANK B.G no.A89G0P6181150001 Rs.3,00,000/- Pgeno:-76
12	Tender Fee Rs 10,000/- in form of DD as per Clause 3(a).	CANARA BANK D.D no:-578900 Rs.10,000/- Pgeno:-1
13	Self attested copies of the Audited Annual Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 crores for any three of the last four consecutive financial years. (Auditor/ C.A. Certificate of turnover will not be accepted). As per Clause 3(l)	F.Y.-2014-2015 Rs.166.3 (in crore) Pgeno:-86 F.Y.-2015-2016 Rs.163.88(in crore) Pgeno:-83 F.Y.-2016-2017 Rs.178.95(in crore) Pgeno:-80
14	Self attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(m).	F.Y.-2015-2016 Pgeno:-67 F.Y.-2016-2017 Pgeno:-66 F.Y.-2017-2018 Pgeno:-65
15	Self attested copy of PAN Card of the Bidder Company. As per Clause 3(p)	PAN no. 'AAACU0405C' pgeno:-6
16	Self attested copy of Certificate of valid GST registration of the bidder company. As per Clause 3(q)	GST no:-09AAACU0405C1ZZ pgeno.69
17	Affidavit (with stamp) declaration regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT).	Scanned copy of notarised affidavit regarding Acceptance of Tender Conditions is submitted as per annexure IV of NIT. (Pg. no 89)
	The facts in clause No-1 to 10 and 17 of the provided sheet has been complied with due diligence and care, on the basis of document provided by BMSICL, inspite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to notice in due time if any discrepancies are observed for rectification.	

Amr
14/6/18

PK
12/6/18

MM
12/6/18

Vijay
12/6/18

Primes
12/6/18

Ant
12/6/18

Ad
12/6/18

AS
11-18